Clinical trial
Bevacizumab + CHOP-Rituximab in Untreated Mantle Cell Lymphoma
NCT00401817 · Weill Medical College of Cornell University, Other · Completed
Key facts
| NCT number | NCT00401817 |
|---|---|
| Title | Bevacizumab + CHOP-Rituximab in Untreated Mantle Cell Lymphoma |
| Official title | Phase II Study of Bevacizumab Plus CHOP-Rituximab in Patients With Untreated Mantle Cell Lymphoma (NHL) |
| Lead sponsor | Weill Medical College of Cornell University, Other |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Untreated Mantle Cell Lymphoma |
| Intervention type | Drug |
| Interventions | Bevacizumab, Rituximab, CHOP |
| Enrollment | 11 |
| Start date | Nov 1, 2007 |
| Primary completion | Jul 1, 2011 |
| Completion | Nov 1, 2013 |
| First posted | Nov 22, 2006 |
| Last update posted | Oct 20, 2017 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: